CRISPR Therapeutics AG (CRSP) is listed on NasdaqGM in the Healthcare sector Β· Biotechnology industry. The current price is 56.54, down -0.67% from the previous close. Market cap is approximately $5.5B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
CRSP's ROE at -26.10% lags the market. ROE stuck below 5% for 1-2 years can be a value trap signal β verify the fundamental story before assuming recovery.
CRSP's D/E at 44.87 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
CRISPR Therapeutics AG's 1041.40% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
Demographic-driven structural demand growth is a long-running tailwind for healthcare.
CRISPR Therapeutics AG sits in the lower 36% of its 52-week range (44.12β78.48). The stock has pulled back from its highs; whether that reflects sector-wide conditions or a company-specific issue is the first thing to establish.
The day's high-to-low spread reached 3.73%, with a -0.67% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
CRISPR Therapeutics AG (CRSP) is listed on NasdaqGM, with recent volume of 547,187 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.